ArticleMedical hypotheses2020
The possible immunoregulatory and anti-inflammatory effects of selective serotonin reuptake inhibitors in coronavirus disease patients.
Article in Medical hypotheses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- Repurposing Selective Serotonin Reuptake Inhibitors as Immunomodulators: Effects on Macrophage Activation and Polarization.Molecular neurobiology · 2026Review
- Protective effects of psychiatric medications against COVID-19 mortality before vaccines.PloS one · 2025Article
- Depression clinical trials worldwide: a systematic analysis of the ICTRP and comparison with ClinicalTrials.gov.Translational psychiatry · 2024Review
- Metabolomics-directed nanotechnology in viral diseases management: COVID-19 a case study.Pharmacological reports : PR · 2023Review
- The impact of preexisting psychiatric disorders and antidepressant use on COVID-19 related outcomes: a multicenter study.Molecular psychiatry · 2023Article
- Inhibitory effects of fluoxetine on the secretion of inflammatory mediators and JAK/STAT3 and JNK/TLR4 gene expression.Molecular biology reports · 2023Article
- Quantum tunnelling in the context of SARS-CoV-2 infection.Scientific reports · 2022Article
- Hypothesis-Agnostic Network-Based Analysis of Real-World Data Suggests Ondansetron is Associated with Lower COVID-19 Any Cause Mortality.Drugs - real world outcomes · 2022Article
- Antidepressant Drugs and COVID-19: A Review of Basic and Clinical Evidence.Journal of clinical medicine · 2022Review
- Neutralizing the free radicals could alleviate the disease severity following an infection by positive strand RNA viruses.Cell stress & chaperones · 2022Review
- Effect of Fluvoxamine on Interleukin-6 Levels in COVID-19 Patients Hospitalized in ICU: A Randomized Clinical Trial.Tanaffos · 2022Article
- Selective serotonin reuptake inhibitors: New hope in the fight against COVID-19.Frontiers in pharmacology · 2022Review
- Ongoing Use of SSRIs Does Not Alter Outcome in Hospitalized COVID-19 Patients: A Retrospective Analysis.Journal of clinical medicine · 2021Article
- Psychotropics and COVID-19: An analysis of safety and prophylaxis.L'Encephale · 2021Article
- Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants.JAMA network open · 2021Article
- Fluoxetine hydrochloride loaded lipid polymer hybrid nanoparticles showed possible efficiency against SARS-CoV-2 infection.International journal of pharmaceutics · 2021Article
- Does serotonin deficiency lead to anosmia, ageusia, dysfunctional chemesthesis and increased severity of illness in COVID-19?Medical hypotheses · 2021Article
- SARS-CoV-2 early infection signature identified potential key infection mechanisms and drug targets.BMC genomics · 2021Article
- Immunological Interfaces: The COVID-19 Pandemic and Depression.Frontiers in neurology · 2021Review
- 5-Hydroxytryptamine, Glutamate, and ATP: Much More Than Neurotransmitters.Frontiers in cell and developmental biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While researchers are struggling to develop a vaccine for coronavirus disease, it is important to evolve effective therapeutic strategies to save lives. The majority of coronavirus disease deaths are due to pneumonia. Mostly, stress and depression are associated with coronavirus disease infection and thus, resulting in weakening of patients' immune response and hence, more severe respiratory symptoms or even death. We propose using a class of antidepressants named selective serotonin reuptake inhibitors for their reported potential antiviral effect, modulatory effect of respiratory symptoms, antioxidant properties and immunoregulatory effects beside their main action as antidepressant. In addition, the low cost of selective serotonin reuptake inhibitors might add a benefit for coronavirus disease patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.